|
|
Vaccine Detail
|
MenHibrix |
| Vaccine Information |
- Vaccine Name: MenHibrix
- Target Pathogen: Neisseria meningitidis
- Target Disease: Meningitis
- Product Name: Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine
- Tradename: MenHibrix
- Manufacturer: GlaxoSmithKline Biologicals
- Vaccine Ontology ID: VO_0000031
- Type: Conjugate vaccine
- Status: Licensed
- Location Licensed: United States
- Host Species for Licensed Use: Human
- Antigen: Neisseria meningitidis serogroup C and Y capsular polysaccharide antigens and
Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]) (FDA: MenHibrix).
- Immunization Route: Intramuscular injection (i.m.)
- Approved Age for Licensed Use: 6 months to 18 years (FDA: MenHibrix)
|
| Host Response |
|
|
| References |
FDA: MenHibrix: FDA: MenHibrix Package insert [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm308566.htm]
|
|
